Hansa Biopharma — Januar 2025
-
Absolut ingen anbefaling, men for at følge op (27/12 11:52), så er det: Vicore Pharma:
Home - Vicore Pharma
This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I’m a bike messenger […]
Vicore Pharma (vicorepharma.com)
Vicore Pharma virksomhedspræsentation, November, 2024:
-
Hansa Biopharma: "Positive fase 2-analyser fremhæver det terapeutiske potentiale af imlifidase i Guillain-Barrés syndrom".https://www.neurologylive.com/view/positive-phase-2-analyses-highlight-therapeutic-potential-imlifidase-guillain-barr-syndrome
-
Biotek-snakken er ikke synlig, så poster her. Vicore Pharma: Unikt fyndläge trots hög risk
Publicerad: 18. dec. 2024, 10.32
Uppdaterad: 20. dec. 2024, 19.05 -
Jeg har købt Cinclus Pharma (en lille position) på faldet i dag ...
"Movestic Livförsäkring flaggar för ett ägande om precis över 5 procent av rösterna i läkemedelsutvecklingsbolaget Cinclus Pharma. Det framgår av ett flaggningsmeddelande. ... 3 jan. 17:03 ∙ Finwire"
-
Financial Position Analysis (fra Simplywall):
Short Term Liabilities: CINPHA's short term assets (SEK656.8M) exceed its short term liabilities (SEK44.4M).
Long Term Liabilities: CINPHA's short term assets (SEK656.8M) exceed its long term liabilities (SEK7.1M).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind